Главная
Рынки
Графики и идеи
Алготрейдинг
Новости
Store
Брокеры
Скачать
Экономический календарь
Торговые сигналы
Вебтерминал
Нажмите
/
для поиска: @user, $symbol, ...
Поиск
Вход
Создать аккаунт
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CCCC
#2959
C4 Therapeutics, Inc.
2.7
0
-1.46%
Сектор:
Базовая:
Валюта прибыли:
Дневной диапазон
Годовой диапазон
Дневное изменение
-1.46%
Месячное изменение
+26.17%
6-месячное изменение
+5.06%
Годовое изменение
+4.25%
Предыдущее закрытие
2.7
4
Open
2.7
0
Bid
Ask
Low
2.7
0
High
2.7
0
Объем
57
Рынки
Рынок акций США
Здравоохранение
CCCC
Open full chart
Financials
Overview
Отчетность
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
70.59 M
70.99 M
71.01 M
71.17 M
96.91 M
97.58 M
—
Valuation ratios
Enterprise value
342.71 M
200.06 M
62.32 M
23.62 M
156.34 M
111.77 M
354.05 M
Price to earnings ratio
-3.35
-2.37
-1.08
-0.9
-1.32
-1.5
-4.81
Price to sales ratio
11.28
7.02
2.8
2.93
5.25
—
—
Price to cash flow ratio
4.88
3.83
1.39
1.15
1.67
1.6
5.82
Price to book ratio
0.36
1.16
0.12
0.12
0.21
0.62
1.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.07
0.1
0.08
0.09
0.12
0.06
0.35
Return on equity %
0.1
0.16
0.13
0.15
0.21
0.08
0.57
Return on invested capital %
76.84
112.39
92.51
98.05
140.69
87
418.25
Gross margin %
100
100
100
100
100
100
400
Operating margin %
183.86
728.39
402.93
440.99
306.43
210.1
1 360.45
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
160.57
667.82
363.66
402.6
286.43
185.97
1 238.66
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.31
5.71
5.7
5.06
5.76
7.81
24.32
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.02
0.02
0.04
0.04
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.35
0.26
0.47
0.17
0.43
0.27
1.34
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.08
3.85
3.31
3.14
2.75
3.58
12.79
Net current asset value per share
3.92
3.72
3.28
3.16
2.85
3.11
12.41
Tangible book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Working capital per share
3.3
3.06
2.71
2.54
2.36
2.72
10.32
Book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Новости
Barclays eleva preço-alvo das ações da C4 Therapeutics após avanço em ensaios
Barclays raises C4 Therapeutics stock price target on trial progress
TD Cowen reitera classificação de Compra para ações da C4 Therapeutics
TD Cowen reiterates Buy rating on C4 Therapeutics stock
Lucro da C4 superou projeções por $0,11; receita supera estimativas
C4 earnings beat by $0.11, revenue topped estimates
Brookline Capital eleva preço-alvo da C4 Therapeutics com avanço em ensaios
Brookline Capital raises C4 Therapeutics stock price target on trial progress
C4 Therapeutics doses first patient in phase 2 myeloma trial
Diretor médico da C4 Therapeutics vende ações no valor de US$ 22.200
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock
C4 Therapeutics avançará testes de cemsidomide para mieloma múltiplo